WCN26-6562 Rationale and protocol of the Japan Kidney Association–Pemafibrate Intervention for Chronic Kidney Disease Patients Study (JKAPI-CKD Study)

Read full text Summarise with VIRAT
Authors: Sho Kinguchi, Kouichi Tamura, Yuichiro Yano, Naoki Kashihara
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

In recent years, elevated triglyceride (TG) levels have attracted increasing attention as a residual cardiovascular risk factor in patients with chronic kidney disease (CKD). Pemafibrate, a selective peroxisome proliferator-activated receptor αmodulator and a novel therapeutic option for hypertriglyceridemia in patients with CKD, has been reported to cause fewer kidney-related adverse events than conventional fibrates. Although appropriate management of hypertriglyceridemia may contribute to improved renal outcomes, evidence for the renoprotective effects of pemafibrate has not yet been established.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Peroxisome Proliferator-Activated Receptors Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104862–104862
Publication date
25 March 2026
Language
EN